Highest risk CLL patients may benefit from CAR T with BTK inhibitor
Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...
sicklecellanemianews47m
Most patients free of vaso-occlusive crises for years after Casgevy dose
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Foreign Policy38m
Foreign Policy Magazine - home page
This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. Your guide to the most important world stories of ...